<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117800">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02084069</url>
  </required_header>
  <id_info>
    <org_study_id>UMSU-Cardiology-2</org_study_id>
    <nct_id>NCT02084069</nct_id>
  </id_info>
  <brief_title>Atrovastatin for Preventing Atrial Fibrillation Following Open Cardiac Valve Repair</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urmia University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Urmia University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the investigation is to determine whether Atrovastatin as anti-inflammatory
      agent can be effective in preventing from atrial fibrillation incidence in patients whom
      undergone open cardiac surgery for their heart valve repair.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Atrial fibrillation incidence after open cardiac valve repair</measure>
    <time_frame>Within 5 days after open cardiac valve repair</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Heart Valve Diseases</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 40 mg once daily from 3 days before surgery up to five days after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than 25 y/o

          -  No occurrence of intra- or post-operative cardiopulmonary arrest

          -  Not consuming drugs affecting atrial rhythm

          -  Having sinus rhythm before surgery

          -  Lack of paroxysmal atrial fibrillation history

          -  Only undergo heart valve surgery

          -  Lack of considerable heart ischemia needed atorvastatin use

          -  Routine cares in ward, post-operative ward, and intensive care unit were done

        Exclusion Criteria:

          -  Lesser than 25 y/o

          -  History of atrial fibrillation

          -  History of taking anti-arrhythmic drugs

          -  History of implementing pacemakers

          -  Severe heart failure

          -  Renal failure

          -  Hepatic failure

          -  Severe pulmonary diseases

          -  Heart block or bradyarrhythmia

          -  Routine cares in ward, post-operative ward, and intensive care unit were not  done

          -  Performing concomitant cardiac surgery except valve repair

          -  Having considerable heart ischemia needed atorvastatin use
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seyyed-al-Shohada Heart Center</name>
      <address>
        <city>Urmia</city>
        <state>West-Azerbaijan</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://umsu.ac.ir</url>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>March 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
